Overview

Paclitaxel in Combination With Carboplatin Versus Paclitaxel Plus Epirubicin in Metastatic Breast Cancer

Status:
Unknown status
Trial end date:
2016-12-01
Target enrollment:
0
Participant gender:
Female
Summary
Paclitaxel plus Epirubicin in metastatic breast cancer is a recommended scheme in National Comprehensive Cancer Network (NCCN) guideline. Paclitaxel in Combination with Carboplatin is also effective in Metastatic Breast Cancer (MBC) in some clinical study with small sample.
Phase:
Phase 4
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Tianjin Medical University Cancer Institute and Hospital
Treatments:
Albumin-Bound Paclitaxel
Carboplatin
Epirubicin
Paclitaxel
Criteria
Inclusion Criteria:

- female ≥ 18 years old, ECOG 0-2 or KPS≥60, Expected lifetime more than 12 weeks.

Exclusion Criteria:

- Pregnancy, Paclitaxel, platinum and anthracycline-based drugs' allergy, Severe
Infection.